Active international collaboration has facilitated the rise of the Asia Pacific region in global clinical research. In the first two parts of this blog series, we’ve discussed how Japan and South Korea – whose clinical research environments vary significantly from each other – share many common interests in their pursuit for advancing clinical R&D. The open flow of data between these countries, and their desire for expanding research, has resulted in a dynamic climate for conducting clinical trials.
Japan has taken significant steps in establishing itself as a major player in the global clinical research community, driving the demand for more clinical trials across East Asia as a result. By officially acknowledging and seeking clinical data from the Asia Pacific region, Japan is facilitating a dialogue with one of the most powerful and capable clinical trial landscapes in the world: South Korea.
In June of 2014, Japan’s prime minister, Shinzo Abe said he wanted to increase the market for robots in Japan to $22 billion by 2020 and launched a “robot revolution realization council” to create a five-year blueprint to push the industry forward. On the heels of this announcement the New Energy and Industrial Technology Development Organization (NEDO) has recruited Kawasaki and Panasonic to create a robot to perform more intricate tasks, including brain surgery. Their goal is to have products in clinical trials as soon as 2019. This increase in robotic advancement is expected to minimize error and maximize efficiency and precision during medical procedures. In addition, the use of robots to complete jobs usually done by humans has the potential to decrease overall costs in the coming years.